What is Touchstone Biosciences?
Touchstone Biosciences operates as a specialized contract research organization, providing critical in vitro and in vivo ADME/Tox services, bioanalysis, and formulation development. The company serves as a vital link in the drug discovery and clinical development pipeline, offering high-fidelity data interpretation and study design. By maintaining a team of seasoned scientists with deep pharmaceutical backgrounds, Touchstone Biosciences differentiates itself through technical precision and a client-centric approach to complex biological testing. Their market position is defined by a commitment to high-quality, cost-effective research support that accelerates the transition of therapeutic candidates from the laboratory to clinical trials.
How much funding has Touchstone Biosciences raised?
Touchstone Biosciences has raised a total of $42K across 1 funding round:
Debt
$42K
Debt (2021): $42K with participation from PPP
Key Investors in Touchstone Biosciences
PPP
Public-Private Partnership
What's next for Touchstone Biosciences?
With the infusion of this recent capital, Touchstone Biosciences is poised to enter a new phase of operational maturity. The strategic roadmap likely involves expanding its laboratory infrastructure to accommodate increased demand for bioanalytical services and enhancing its proprietary formulation development capabilities. As the firm navigates the complexities of the drug development lifecycle, this funding provides the necessary runway to invest in advanced instrumentation and talent acquisition. Future growth will likely focus on deepening its footprint in the U.S. market while maintaining the rigorous quality standards required for regulatory-compliant clinical development support. The company remains focused on optimizing its service portfolio to address the evolving needs of biotech and pharmaceutical innovators.
See full Touchstone Biosciences company page
